BBNX Beta Bionics, Inc.
Beta Bionics, Inc. (BBNX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 52% planned / 48% discretionary
Largest single sale: $680.7K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Hopman Mark | Chief Commercial Officer | Sell 10b5-1 | 775 | $15.52 | $12.0K | 86,382 −0.9% of holding | |
| Hopman Mark | Chief Commercial Officer | Sell 10b5-1 | 36,870 | $18.46 | $680.7K | 87,157 −29.7% of holding | |
| Saint Sean | President & CEO | Sell 10b5-1 | 5,641 | $20.08 | $113.3K | 398,429 −1.4% of holding | |
| Saint Sean | President & CEO | Sell | 16,867 | $19.11 | $322.4K | 404,070 −4% of holding | |
| Feider Stephen | Chief Financial Officer | Sell | 6,675 | $19.11 | $127.6K | 159,378 −4% of holding | |
| Hopman Mark | Chief Commercial Officer | Sell | 5,327 | $19.11 | $101.8K | 124,027 −4.1% of holding | |
| Mensinger Mike | Chief Product Officer | Sell | 4,375 | $19.11 | $83.6K | 180,040 −2.4% of holding | |
| Russell Steven Jon | Chief Medical Officer | Sell | 4,221 | $19.11 | $80.7K | 169,628 −2.4% of holding | |
| Feider Stephen 2 fills | Chief Financial Officer | Sell 10b5-1 | 9,792 | $17.03 | $166.8K | 166,053 −5.6% of holding | |
| Feider Stephen 2 fills | Chief Financial Officer | Sell 10b5-1 | 10,208 | $17.05 | $174.0K | 166,053 −5.8% of holding | |
| Jones Christy | Director | Sell 10b5-1 | 1,406 | $15.00 | $21.1K | 25,994 −5.1% of holding | |
| Hopman Mark | Chief Commercial Officer | Sell 10b5-1 | 1,258 | $15.01 | $18.9K | 129,354 −1% of holding | |
| Jones Christy | Director | Sell 10b5-1 | 2,811 | $14.00 | $39.4K | 27,400 −9.3% of holding | |
| Hopman Mark | Chief Commercial Officer | Sell 10b5-1 | 275 | $12.31 | $3.4K | 130,612 −0.2% of holding | |
| Saint Sean | President & CEO | Sell | 16,872 | $12.61 | $212.7K | 420,937 −3.9% of holding | |
| Feider Stephen | Chief Financial Officer | Sell | 6,676 | $12.61 | $84.2K | 166,053 −3.9% of holding | |
| Hopman Mark | Chief Commercial Officer | Sell | 5,329 | $12.61 | $67.2K | 130,887 −3.9% of holding | |
| Mensinger Mike | Chief Product Officer | Sell | 4,378 | $12.61 | $55.2K | 184,415 −2.3% of holding | |
| Russell Steven Jon | Chief Medical Officer | Sell | 4,222 | $12.61 | $53.2K | 173,849 −2.4% of holding | |
| Lezack Adam | Director | Sell 10b5-1 | 998 | $11.21 | $11.2K | 27,399 −3.5% of holding | |
| Jones Christy | Director | Sell 10b5-1 | 1,998 | $9.95 | $19.9K | 13,246 −13.1% of holding | |
| Lezack Adam | Director | Sell 10b5-1 | 1,000 | $9.95 | $10.0K | 11,432 −8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.